Displaying drugs 1101 - 1125 of 1981 in total
KN-001
Investigational
CEB-01
CEB-01 is a biocompatible polymeric PLGA nanofiber membrane containing the active substance 7-ethyl-10-hydroxycamptothecin
Investigational
YT-001
Investigational
BJ-001
BJ-001 is a recombinant human interleukin-15/IL-15 receptor alpha complex with linked integrin-binding motif.
Investigational
FF-10501-01
FF-10501-01 is a novel, selective inosine monophosphate dehydrogenase (IMPDH) inhibitor with anticancer activity. FF-10501-01 is under investigation in clinical trial NCT03486353 (A Study of FF-10501-01 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome).
Investigational
Uzansertib
Uzansertib is under investigation in clinical trial NCT02587598 (Study of INCB053914 in Subjects With Advanced Malignancies).
Investigational
Lumicitabine
Lumicitabine is under investigation in clinical trial NCT03010059 (A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and Tablet) Compared to Their Respective Current Formulations, and to Assess the Effect of Food on the Pharmacokinetics of the 2 New Concept Formulations).
Investigational
ALS-08
ALS-08 is a proprietary creatine-derivative that is being developed as a potential therapeutic for amyotrophic lateral sclerosis (ALS). It is being developed by Avicena Group, Inc.
Investigational
CT-011
CT-011 is a humanized monoclonal antibody directed against a B7 family-associated protein, in patients with advanced haematological malignancies. It is directed against human PD-1 (programmed cell death 1; PDCD1), with immunomodulating and antitumor activities.
Investigational
ELX-02
ELX-02 is under investigation in clinical trial NCT03309605 (Phase 1 Study of ELX-02 in Healthy Adult Subjects).
Investigational
AT-001
AT-001 is under investigation in clinical trial NCT03062384 (AT-001 for Long-term Preservation of Brain Health in Aging).
Investigational
EMB-01
EMB-01 is under investigation in clinical trial NCT03797391 (A Dose Escalation Study of EMB-01 in Participants With Advanced/metastatic Solid Tumors).
Investigational
CB-010
CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19. It is being investigated for the treatment of follicular lymphoma.
Investigational
EF-022
EF-022 is a modified version of vitamin D binding protein macrophage activator, with potential antineoplastic and anti-angiogenic activities.
Investigational
AB-001
Investigational
VCN-01
VCN-01 is an investigational, genetically modified human adenovirus encoding human PH20.
Investigational
OT-004
Investigational
CT-001
Investigational
Mazorelvimab
Investigational
Domagrozumab
Domagrozumab is under investigation in clinical trial NCT01616277 (A Phase 1 Study To Evaluate The Safety And Tolerability Of PF-06252616 In Healthy Subjects).
Investigational
Borocaptate
Investigational
Matched Iupac: … {1,4}.0^{2,6}.0^{2,7}.0^{2,12}.0^{3,5}.0^{3,6}.0^{4,9}.0^{4,11}.0^{5,8}.0^{5,9}.0^{6,8}.0^{7,10}.0^{8,10 ... }.0^{9,11}.0^{10,12}.0^{11,12}]dodecaborane-12-thiol ... 1lambda5,2lambda5,3lambda5,4lambda5,5lambda5,6lambda5,7lambda5,8lambda5,9lambda5,10lambda5,11lambda5,12lambda6-nonadecacyclo[5.4.1.0^{1,3}.0^ …
BS-001
BS-001 is a recombinant oncolytic herpes simplex virus type II (OH2) therapeutic injection (Vero cell) for human use (rHSV2hGM-CSF).
Investigational
AL-034
AL-034 (TQ-A3334) is an oral toll-like receptor 7 agonist developed for the treatment of chronic hepatitis B (CHB) viral infection.
Investigational
EI-001
Investigational
Displaying drugs 1101 - 1125 of 1981 in total